Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 25:70:135-141.
doi: 10.1016/j.euros.2024.10.010. eCollection 2024 Dec.

Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer

Teemu J Murtola  1   2 , Aino Siltari  1   3 , Paavo Raittinen  4 , Teuvo L J Tammela  1   2 , Stig Linder  5   6 , Anita Csizmarik  7 , Gero Kramer  8 , Tibor Szarvas  7   9
Affiliations

Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer

Teemu J Murtola et al. Eur Urol Open Sci. .

Abstract

Background and objective: Prostate-specific antigen (PSA) is of limited value as a surrogate marker for overall survival (OS) in prostate cancer (PC). Serum thymidine kinase 1 (sTK1) is an enzyme expressed by actively dividing cells. Our aim was to evaluate the value of sTK1 as prognostic biomarker in metastatic hormone-sensitive PC (mHSPC) and metastatic castration-resistant PC (mCRPC).

Methods: sTK1 was examined in three cohorts: (1) 43 men with de novo mHSPC managed with androgen deprivation monotherapy; (2) 99 patients with mCRPC managed with androgen receptor signaling inhibitors (ARSIs); and (3) 98 patients with mCRPC treated with docetaxel. sTK1 levels were determined at treatment initiation. OS was evaluated using Cox regression analysis.

Key findings and limitations: In the mHSPC cohort, sTK1 levels in the highest quartile were associated with OS (hazard ratio [HR] 7.77, 95% confidence interval [CI] 2.25-26.9) in comparison to the lowest quartile after multivariable adjustment for age, Gleason score, and PSA. Similarly, sTKI was associated with poor OS in the mCRPC group treated with ARSIs (upper quartile: HR 5.22, 95% CI 2.23-12.2) after multivariable adjustment for age, PSA, and Eastern Cooperative Oncology Group performance status. In the docetaxel-treated mCRPC group the association between OS and sTK1 was lower but still significant (multivariable-adjusted HR 2.28, 95% CI 1.13-4.60). Limitations include the nonrandomized inclusion of patients for different treatments, which could lead to selection bias.

Conclusions and clinical implications: sTK1 predicted OS in mHSPC and mCRPC, demonstrating additional value over established clinical risk factors. sTK1 should be measured in randomized clinical trials of treatments for advanced PC to validate its predictive value.

Patient summary: We found that for patients with metastatic prostate cancer, high levels of a protein called TK1 that is involved in cell division was linked to higher risk of death. Our findings need to be confirmed in other studies.

Keywords: Antiandrogen; Docetaxel; Prostate cancer; Survival; Thymidine kinase 1; Treatment prediction.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival by serum TK1 quartiles among 197 men diagnosed with metastatic castrate-resistant prostate cancer. The difference in survival among the quartiles is statistically significant (p < 0.001).
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Shelley M., Harrison C., Coles B., Staffurth J., Wilt T.J., Mason M.D. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev. 2006;2006 - PubMed
    1. Cornford P., van den Bergh R.C.N., Briers E., et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–282. - PubMed
    1. Cornford P, Tilki D, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Arnhem, The Netherlands: European Association of Urology; 2024.
    1. Ferretti S., Mercinelli C., Marandino L., Litterio G., Marchioni M., Schips L. Metastatic castration-resistant prostate cancer: insights on current therapy and promising experimental drugs. Res Rep Urol. 2023;15:243–259. - PMC - PubMed